ArticleJACC. Asia2026
Circumferential Ultrasonic Renal Denervation Targeting Main Renal Arteries and Branches: A First-in-Human Study.
Article in JACC. Asia, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This study assessed the feasibility and safety of ultrasound renal denervation (uRDN) targeting both main and branch renal arteries to treat uncontrolled hypertension. A circumferential uRDN system was evaluated in a porcine model (n = 6) and a first-in-human study (n = 5). Endpoints included the incidence of device-related adverse events and changes in blood pressure. Preclinical studies revealed a favorable safety profile and >97% reduction in renal norepinephrine levels. In the human study, all procedures were technically successful without device-related adverse events. At 2 and 6 months, 24-hour ambulatory systolic/diastolic blood pressure decreased by 8.8 (95% CI: 0.98-16.62)/4.6 (95% CI: -1.83 to 11.03) mm Hg and 16 (95% CI: 1.18-30.82)/8 (95% CI: 0.76-15.24) mm Hg , respectively. These preliminary findings support the feasibility and safety of this circumferential uRDN approach for uncontrolled hypertension. (A Prospective Feasibility Trial Investigating the Use of Hantong Medical uRDN System in Patients With Uncontrolled Hypertension (Hammer HTN; ChiCTR2400093088).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.